Product Documentation · EXO Line
RENOVÓ
EXO Line
A structured series of vesicle-mediated signalling formulations, each defined by biological origin and environmental alignment rather than concentration alone.
FormulationsEXO-10 · EXO-30 · EXO-50 · EXO-90 · EXO-180
Source MaterialsWharton's Jelly · Umbilical Cord Blood Plasma
ContextRegulated Clinical & Personal Use
R

Contents

  • I
    EXO-10Topical · 12.23B · WJ
  • II
    EXO-30Topical · 30B · WJ
  • III
    EXO-50Topical + Systemic · 50B · WJ
  • IV
    EXO-90Systemic · 90B · Endothelial
  • V
    EXO-180Advanced Systemic · 180B · Endothelial
Platform Note

RENOVÓ formulations are not ranked by superiority. Each exists to align with a specific biological environment. Selection begins with context — not concentration.

Wharton's Jelly Derived — EXO-10, EXO-30, EXO-50
Cord Blood Plasma · Endothelial Stem Cell Derived — EXO-90, EXO-180
10
Wharton's Jelly · Topical
EXO-10
The entry presentation of the Wharton's jelly line. Focal topical application, smaller treatment areas, introductory protocols.
Particle Count (NTA)
12.23 ±1.73B
Lot 20A0021 · 50–150 nm window
Format
Lyophilised
Powder for reconstitution
Fill Volume
5 mL
Post-reconstitution
Additional Content
20 Amino Acids
Amino acid complement included
Application
Topical
Formulated for surface application
Source
Wharton's Jelly
Human umbilical cord

EXO-10 is the entry presentation of the RENOVÓ Wharton's jelly line — a composition of twenty amino acids with Wharton's jelly derived exosomes, reconstituted with copper peptide solution. Its nominal designation is 10 billion exosomes; the Certificate of Analysis for Lot 20A0021 reports a measured particle count of 12.23 ±1.73B.

Its configuration is deliberate rather than reduced. EXO-10 is specified for focal topical application — smaller treatment areas, single-region skin and hair contexts, and introductory protocols where the EXO-30 concentration is not the appropriate starting point.

WJ
Source Environment
Wharton's Jelly
Factors Reported in Published Characterisation of This Source Material
TGF-βFGFPDGFECM Structuring
EXO-10 shares the source environment of EXO-30 and EXO-50 — Wharton's jelly, the perinatal connective tissue matrix of the umbilical cord. The cargo profile follows the source material rather than the tier; what differs at this presentation is particle concentration and the accompanying amino acid complement. RENOVÓ's per-lot testing establishes source, particle concentration and size distribution.
Focal topical application. Smaller treatment areas. Single-region skin and hair contexts. Introductory protocol design.
II
30
Wharton's Jelly · Topical
EXO-30
Surface-oriented vesicle signalling, formulated for skin and hair tissue interfaces.
Particle Count (NTA)
30 Billion
Particles per vial · 50–150 nm window
Format
Lyophilised
Powder for reconstitution
Fill Volume
5 mL
Post-reconstitution
Additional Content
Collagen
Collagen peptides included
Application
Topical
Formulated for surface application
Source
Wharton's Jelly
Human umbilical cord

EXO-30 is the surface-layer formulation within the RENOVÓ EXO series. Derived from Wharton's jelly of the human umbilical cord, its exosome populations carry the signalling characteristics of connective tissue and extracellular matrix environments — making it the formulation most precisely aligned with skin and hair tissue contexts.

The inclusion of collagen peptides reinforces this surface alignment, supporting the structural and architectural language native to dermal environments. EXO-30 does not transition into systemic contexts. Its function is deliberate, defined, and surface-specific.

WJ
Source Environment
Wharton's Jelly
Factors Reported in Published Characterisation of This Source Material
TGF-βFGFPDGFECM Structuring
Wharton's jelly is a perinatal connective tissue matrix within the umbilical cord. Vesicle populations isolated from this tissue have been reported in the literature to carry cargo associated with structural tissue organisation and fibroblast signalling — the signalling vocabulary of perinatal connective tissue. RENOVÓ's per-lot testing establishes source, particle concentration and size distribution.
Skin and hair tissue interfaces. Dermal regenerative environments. Surface-level extracellular matrix contexts. Collagen-oriented signalling.
III
50
Wharton's Jelly · Topical + Systemic
EXO-50
Foundational systemic formulation. The baseline for internal regenerative environments.
Particle Count (NTA)
50 Billion
Particles per vial · 50–150 nm window
Format
Lyophilised
Powder for reconstitution
Fill Volume
5 mL
Post-reconstitution
Additional Content
None
Pure exosome formulation
Application
Topical + Systemic
Formulated for surface and non-topical contexts
Source
Wharton's Jelly
Human umbilical cord

EXO-50 is the foundational systemic formulation within the RENOVÓ EXO series — the first formulation to extend beyond surface-level contexts into internal regenerative environments, while remaining compatible with topical application.

Derived from Wharton's jelly, EXO-50 carries the connective tissue and matrix-associated signalling of its source environment into broader tissue-repair contexts. It represents the baseline for Wharton's jelly–derived systemic use, prior to the transition into endothelial-classified formulations.

WJ
Source Environment
Wharton's Jelly
Factors Reported in Published Characterisation of This Source Material
TGF-βFGFPDGFMusculoskeletal Contexts
At the EXO-50 tier, Wharton's jelly–derived signalling extends into connective tissue and musculoskeletal environments — carrying tissue-repair coordination and fibroblast communication into broader internal regenerative contexts, without transitioning into endothelial-dominant signalling profiles.
Topical and systemic environments. Connective tissue and musculoskeletal contexts. Baseline internal regenerative consideration. Tissue-repair coordination.
IV
90
Cord Blood Plasma · Endothelial Stem Cell · Systemic
EXO-90
Entry point into endothelial-derived signalling. The transition into vascular and systemic environments.
Particle Count (NTA)
90 Billion
Particles per vial · 50–150 nm window
Format
Lyophilised
Powder for reconstitution
Fill Volume
1 mL
Post-reconstitution
Additional Content
None
Pure exosome formulation
Application
Not for Topical Use
Route determined by the practitioner under applicable law.
Source
Endothelial SC
Umbilical cord blood plasma

EXO-90 marks a deliberate transition within the RENOVÓ EXO series — the shift from connective tissue–oriented Wharton's jelly signalling to the vascular and systemic logic of endothelial stem cell–derived environments.

EXO-90 is derived from umbilical cord blood plasma, endothelial stem cell derived. Published characterisation of endothelial-derived vesicles reports VEGF, ANG-1 and BDNF among cargo constituents. RENOVÓ states the source and the size distribution; it does not assert a physiological effect it has not measured. It is not formulated for topical use; route is determined by the practitioner under applicable law.

ES
Source Environment
Cord Blood Plasma · Endothelial Stem Cells
Factors Reported in Published Characterisation of This Source Material
VEGFANG-1BDNFImmune Modulation
This source environment is umbilical cord blood plasma, endothelial stem cell derived — a starting material carrying the biological logic of circulation, vascular interface communication, and systemic distribution. It is categorised separately from the Wharton's jelly connective tissue material used for EXO-10, EXO-30 and EXO-50, due to its fundamentally distinct signalling orientation.
Internal systemic environments. Vascular and circulatory contexts. Immune signalling and modulation. Neurovascular and neurological interface considerations.
V
180
Cord Blood Plasma · Endothelial Stem Cell · Advanced Clinical
EXO-180
The highest concentration endothelial formulation. Reserved for advanced systemic clinical environments.
Particle Count (NTA)
180 Billion
Particles per vial · 50–150 nm window
Format
Cryopreserved
Frozen · clinical handling required
Fill Volume
1 mL
As supplied
Additional Content
None
Pure exosome formulation
Application
Not for Topical Use
Route determined by the practitioner under applicable law.
Source
Endothelial SC
Umbilical cord blood plasma

EXO-180 represents the apex of the RENOVÓ EXO series — the highest concentration formulation derived from umbilical cord blood plasma, endothelial stem cell derived, positioned for advanced clinical environments where physician oversight, controlled handling, and regulated administration infrastructure are present.

Its cryopreserved format reflects the demands of its intended context. EXO-180 is not a general-use formulation. It is a clinical instrument.

ES
Source Environment
Cord Blood Plasma · Endothelial Stem Cells
Factors Reported in Published Characterisation of This Source Material
VEGFANG-1BDNFSystemic Immune ModulationNeurovascular Communication
At the EXO-180 tier, endothelial-derived signalling encompasses organ-level and circulation-dependent environments — vascular communication, perfusion signalling, systemic immune modulation, and neurovascular interface pathways that reflect the full biological reach of umbilical cord blood plasma, endothelial stem cell derived material.
Advanced systemic clinical environments. Organ-level and circulation-dependent signalling. Physician and clinic-managed contexts only. Professional oversight required.
Formulation Reference
EXO Line — Complete Overview
Formulations sharing a source share a cargo profile. The factor tags on each source panel describe the source material, not the tier — EXO-10, EXO-30 and EXO-50 differ by particle concentration and accompanying composition, as do EXO-90 and EXO-180. The EXO-10 figure below is the measured particle count reported on the Lot 20A0021 Certificate of Analysis; the remaining figures are nominal designations.
ProductSourceQuantityFormatVolumeApplication Context
I
EXO-10With 20 Amino Acids
 Wharton's Jelly 12.23 ±1.73B Lyophilised 5 mL
TopicalFocalSkinHair
II
EXO-30With Collagen Peptides
 Wharton's Jelly 30 Billion Lyophilised 5 mL
TopicalSkinHair
III
EXO-50Foundational Systemic
 Wharton's Jelly 50 Billion Lyophilised 5 mL
TopicalSystemicConnective Tissue
IV
EXO-90Endothelial Entry
 Cord Blood Plasma · Endothelial SC 90 Billion Lyophilised 1 mL
SystemicVascularImmune
V
EXO-180Advanced Clinical
 Cord Blood Plasma · Endothelial SC 180 Billion Cryopreserved 1 mL
Advanced SystemicClinical Only
Platform Philosophy
Formulations are not ranked by strength.
They are defined by where they belong.
Selection within the RENOVÓ EXO series begins with biological context — not concentration. Each formulation exists because its source environment serves a purpose that no other formulation can replicate.
This document is provided for informational and contextual purposes only. RENOVÓ formulations are not intended to diagnose, treat, cure, or prevent any disease or health condition. No administration instructions, protocols, dosing guidance, or treatment recommendations are provided or implied. Regulatory status and permissible contexts of use may vary by jurisdiction. Clinical judgment and applicable regulatory considerations remain the responsibility of the practitioner. This document does not constitute medical advice.
R
RENOVÓ
EXO Line · Product Overview